2020 ASH Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in Patients with R/R AML or HR-MDS Dec 5, 2020
2020 AACR Poster - CG-806, a First-in-Class FLT3/BTK Inhibitor, and Venetoclax Synergize to Inhibit Cell Proliferation and to Induce Apoptosis in Aggressive B-cell Lymphomas Jun 22, 2020
2020 EHA Poster - Early Clinical Findings from a Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with R/R CLL/SLL or NHL Jun 12, 2020
2020 AACR Presentation - Early clinical findings from a Phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with R/R CLL/SLL or NHL Apr 27, 2020
2019 ASH Poster - Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas Dec 9, 2019
2019 ASH Poster - CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells Dec 8, 2019
Aptose Corporate Update at ASH 2019: Early Clinical Observations with CG-806 and APTO-253 Dec 7, 2019
2019 ESH Poster - CG-806 Pan-FLT3/Pan-BTK Inhibitor Simultaneously Suppresses Multiple Oncogenic Signaling Pathways to Treat AML Oct 24, 2019
2019 EHA Poster - CG-806, PRECLINICAL IN VIVO EFFICACY AND SAFETY PROFILE AS A PAN-FLT3 / PAN-BTK INHIBITOR Jun 14, 2019
